Page 36 - 2021_10-Haematologica-web

L. Rasche et al.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.
7. Li J, Stagg NJ, Johnston J, et al. Membrane- proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383-395.
8. Bruins WSC, Zweegman S, Mutis T, van de Donk N. Targeted therapy with immuno- conjugates for multiple myeloma. Front Immunol. 2020;11:1155.
9. Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020. Br J Haematol. 2021;193(4):705-722.
10. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005.
11. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221.
12. Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody- drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889-911.
13. Nooka AK MM, Bahlis N, Weisel K, et al. DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin in combi- nation with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). Hematol Rep. 2020;12(s1):EP955.
14. Popat R, Stockerl-Goldstein K, Abonour R, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with borte- zomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):1419.
15. Trudel S, McCurdy A, Sutherland HJ, et al. Part 1. Results of a dose finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide (POM) and dexamethasone (DEX) for the treatment of relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):725.
16. Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel immune treat- ments in myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):264- 271.
17. XingL,LinL,YuT,etal.AnovelBCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020;34(8): 2150-2162.
18.Kumar SK, Migkou M, Bhutani M, et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma. Blood 2020;136 (Suppl 1):179.
19.Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study bispecifics, trispecifics, and other novel immune treat- ments in myeloma. Focus on monoclonal antibodies targeting B-cell maturation anti- gen (BCMA) in multiple myeloma: update 2020. Blood Cancer J. 2019;9(4):37.
20. Lee HC, Raje NS, Landgren O, et al. Phase 1 study of the anti-BCMA antibody-drug con-
jugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2020;35(1):255-258
21.Bruins WSC, Zheng W, Higgins JP, et al. TAK-169, a novel recombinant immunotox- in specific for CD38, induces powerful pre- clinical activity against patient-derived mul- tiple myeloma cells. Blood. 2020;136(Suppl 1):1363.
22. Vogl DT, Kaufman JL, Holstein SA, et al. TAK-573, an anti-CD38/attenuated Ifnα fusion protein, has clinical activity and mod- ulates the Ifnα receptor (IFNAR) pathway in patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):3197.
23. Sherbenou DW, Aftab BT, Su Y, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016;126(12):4640-4653.
24. Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for anti- body-drug conjugates. Drug Discov Today Technol. 2018;30:85-89.
25. Figueroa-Vazquez V, Ko J, Breunig C, et al. HDP-101, anti-BCMA antibody-drug conju- gate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2020;20 (2):367-378.
26. Strassz A, Raab MS, Orlowski RZ, et al. A first in human study planned to evaluate Hdp-101, an anti-BCMA amanitin antibody- drug conjugate with a new payload and a new mode of action, in multiple myeloma. Blood. 2020;136(Suppl 1):3230.
27. Topp MS, Duell J, Zugmaier G, et al. Evaluation of AMG 420, an anti-BCMA bis- pecific T-cell engager (BiTE) immunothera- py, in R/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study. J Clin Oncol. 2019;37(15_suppl):8007.
neously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bis- pecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):3206.
35. Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396-410.
36. Costa LJ, Wong SW, Bermudez A, et al. First clinical study of the B-cell maturation anti- gen (BCMA) 2+1 T cell engager (TCE) CC- 93269 in patients (Pts) with relapsed/refrac- tory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement 1):143.
37. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myelo- ma. J Clin Invest. 2019;129(6):2210-2221.
38. Da Via MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616-619.
39. Chari A, Berdeja JG, Oriol A, et al. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific anti- body, in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):290.
40. Cohen AD, Harrison SJ, Krishan A, et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):292.
41. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-
28. Topp MS, Mauser M, Einsele H. Outcome of
BCMA Bite (AMG420) therapy in relapse
and refractory multiple myeloma (RRMM)
patients. Blood. 2020;136(Suppl 1):3223. 638.
29. Garfall AL, Usmani SZ, Mateos MV, et al. Updated phase 1 results of teclistamab, a B- cell maturation antigen (BCMA) x CD3 bis- pecific antibody, in relapsed and/or refracto- ry multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):180.
30. Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 bispecific mon- oclonal antibody, induces deep and durable responses in patients with relapsed/refracto- ry multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):291.
31. Buelow B, D'Souza A, Rodriguez C, et al. TNB383B.0001: a multicenter, phase 1, open-label, dose-escalation and expansion study of TNB-383B, a bispecific antibody targeting BCMA in subjects with relapsed or refractory multiple myeloma. Blood. 2019;134(Suppl_1):1874.
32.Rodriguez C, D'Souza A, Shah N, et al. Initial results of a phase I study of TNB- 383B, a BCMA x CD3 bispecific T-cell redi- recting antibody, in relapsed/refractory mul- tiple myeloma. Blood. 2020;136(Suppl 1):293.
33. Harrison SJ, Minnema MC, Lee HC, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Blood. 2020;136(Suppl 1):181.
34. Lesokhin AM, Levy MY, Dalovisio AP, et al. Preliminary safety, efficacy, pharmacokinet- ics, and pharmacodynamics of subcuta-
42. Wäsch R, Munder M, Marks R. Teaming up for CAR-T cell therapy. Haematologica. 2019;104(12):2335-2336.
43. Köhler M, Greil C, Hudecek M, et al. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer. 2018;124(10):2075-2085.
44. Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688-1700.
45. Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti- B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267-2280.
46. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726-1737.
47. Lin Y RN, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multi- ple myeloma: updated results from phase 1 CRB-401 study. Blood. 2020;136(Suppl 1):131.
48. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multi- ple myeloma (RRMM):initial KarMMa results. J Clin Oncol. 2020;38(15-suppl): 8503.
2564
haematologica | 2021; 106(10)